|
Association of PD-L2 expression in human tumors with atezolizumab activity. |
|
|
Honoraria - AstraZeneca; Pfizer |
Consulting or Advisory Role - Roche/Genentech |
Research Funding - Astellas Pharma; AstraZeneca; Genentech; OncoGenex |
|
|
Employment - Roche/Genentech |
Stock and Other Ownership Interests - Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Employment - Roche/Genentech |
Stock and Other Ownership Interests - Roche/Genentech |
Patents, Royalties, Other Intellectual Property - Roche/Genentech |
|
|
Employment - Roche/Genentech |
Stock and Other Ownership Interests - Roche/Genentech |
|
|
Employment - Roche/Genentech |
Stock and Other Ownership Interests - Roche/Genentech |
|
|
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Genentech/Roche; Novartis; Pfizer |
Speakers' Bureau - Genentech/Roche |
Research Funding - ACEA Biosciences (Inst); Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Halozyme (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis |
Research Funding - AstraZeneca/MedImmune; Roche/Genentech |
|
Michiel Simon Van Der Heijden |
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Roche/Genentech (Inst) |
Research Funding - Astellas Pharma (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Novartis |
|
|
Employment - Roche/Genentech |
Stock and Other Ownership Interests - Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Employment - Roche/Genentech |
Stock and Other Ownership Interests - Roche/Genentech |
|
|
Employment - Roche/Genentech |
Stock and Other Ownership Interests - Roche/Genentech |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Roche |
|
|
Employment - Roche/Genentech |
Stock and Other Ownership Interests - Roche/Genentech |
|
|
Consulting or Advisory Role - Amgen; Genentech/Roche; Merck Sharp & Dohme; Novartis |
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst) |
Patents, Royalties, Other Intellectual Property - patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis |
Other Relationship - Bristol-Myers Squibb; Genentech/Roche |